Human Chorionic Gonadotropin Market Report 2026

The human chorionic gonadotropin market size has grown strongly in recent years. It will grow from $1.02 billion in 2025 to $1.11 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing prevalence of infertility, growth of fertility clinics worldwide, long-standing clinical use of hCG in reproductive medicine, rising awareness of hormonal imbalance treatments, availability of natural source hCG products.

The human chorionic gonadotropin market size is expected to see strong growth in the next few years. It will grow to $1.52 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to rising demand for assisted reproductive technologies, increasing adoption of recombinant hormones, growing focus on precision fertility treatments, expansion of online and retail pharmacy distribution, increasing investment in reproductive health research. Major trends in the forecast period include increasing use of hCG in assisted reproductive treatments, rising demand for hormonal therapies in infertility management, growing adoption of recombinant hCG products, expansion of hCG applications in male hormonal disorders, increasing focus on standardized and high-purity hormone formulations.

The increasing prevalence of infertility is expected to drive the growth of the human chorionic gonadotropin (hCG) market in the coming years. Infertility is defined as the inability to conceive after at least one year of consistent, unprotected intercourse. Rising infertility rates are linked to factors such as delayed childbearing, lifestyle changes, environmental exposures, and medical conditions. Human chorionic gonadotropin is used in infertility treatments to stimulate ovulation in women and support testosterone production in men, aiding egg release and improving fertility outcomes. For example, in April 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that infertility affected approximately 17.5% of the adult population worldwide, or roughly one in six people, underscoring the urgent need for accessible, high-quality fertility care. Consequently, the rising infertility rate is propelling the growth of the hCG market.

The growth of the aging population is also expected to support the expansion of the human chorionic gonadotropin market. An aging population refers to an increasing proportion of older individuals within a society, driven by longer life expectancy and declining birth rates. Advances in healthcare have contributed to longer lifespans, increasing the need for hormone support among older adults. Human chorionic gonadotropin is used by this demographic to maintain hormone balance and support testosterone levels. For instance, in January 2024, the Population Reference Bureau, a US-based non-profit organization, reported that the number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, a 47% rise, raising their share of the total U.S. population from 17% to 23%. As a result, the growing aging population is driving the demand for hCG.

In September 2023, Lupin Limited, an India-based pharmaceutical company, acquired five established brands from Menarini for an undisclosed amount. This acquisition enables Lupin to expand its therapeutic portfolio and strengthen its presence in key areas by integrating Menarini’s established hCG-related brands. Menarini Group, based in Italy, is a pharmaceutical and diagnostics company providing products and services related to human chorionic gonadotropin.

Major companies operating in the human chorionic gonadotropin market are Ferring Pharmaceuticals, Merck KGaA, Organon, IBSA Institut Biochimique, Teva Pharmaceutical Industries, Sandoz, Sun Pharmaceutical Industries, Cipla, Zydus Lifesciences, Lupin, Intas Pharmaceuticals, Hikma Pharmaceuticals, Aspen Pharmacare, Menarini Group, Bharat Serums and Vaccines, Serum Institute of India, LG Chem Life Sciences, Dong-A ST, Livzon Pharmaceutical Group, SciGen.

North America was the largest region in the human chorionic gonadotropin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human chorionic gonadotropin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human chorionic gonadotropin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the human chorionic gonadotropin market by increasing the cost of imported active pharmaceutical ingredients, recombinant production inputs, and specialized manufacturing equipment. These impacts are most evident in recombinant hCG products and in regions such as North America and Europe that rely on global biopharmaceutical supply chains. Higher production costs may affect pricing and availability; however, tariffs are also encouraging local manufacturing, regional sourcing of raw materials, and investments in domestic biopharma capabilities, supporting long-term supply security.

The human chorionic gonadotropin market research report is one of a series of new reports that provides human chorionic gonadotropin market statistics, including human chorionic gonadotropin industry global market size, regional shares, competitors with a human chorionic gonadotropin market share, detailed human chorionic gonadotropin market segments, market trends and opportunities, and any further data you may need to thrive in the human chorionic gonadotropin industry. This human chorionic gonadotropin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Human chorionic gonadotropin (hCG) is a hormone produced during pregnancy by the placenta shortly after the embryo implants in the uterus. It plays a vital role in sustaining pregnancy by stimulating the corpus luteum in the ovary to produce progesterone, which supports the uterine lining and prevents its breakdown.

The main production technologies for hCG include natural source extraction and recombinant technology. Recombinant technology is a laboratory technique that combines DNA fragments from different organisms to create new genetic sequences. hCG is used in therapeutic areas such as female infertility treatment, oligospermic treatment, male hypogonadism, and others. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Key end users include fertility clinics, research institutions, and other healthcare facilities.

The human chorionic gonadotropin market includes revenues earned by entities by providing services such as fertility treatments, hormone level monitoring, assisted reproductive technologies (ART), and pregnancy testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.